

Deciphering the Riddles in Nutrition and Cardiovascular Disease

Amelia Carro¹ and Josefa María Panisello²

1. Instituto Corvilud, Asturias, Spain; 2. Fundación para el Fomento de la Salud (FUFOSA), Health Foundation, Madrid, Spain

Abstract

Cardiovascular disease is the leading global cause of death in Western countries, and its development is largely associated with unhealthy dietary patterns. A large body of scientific evidence has reported that nutrition might be the most preventive factor of cardiovascular disease death and could even reverse heart disease. Processes of chronic inflammation and oxidative distress share triggers that are modifiable by nutrition. This review aimed to identify potential targets (food patterns, single foods or individual nutrients) for cardiovascular disease prevention, and analyse the mechanisms implicated in their cardioprotective effects.

Keywords

Nutrition, cardiovascular disease, prevention, inflammation, diet, lifestyle

Disclosure: The authors have no conflicts of interest to declare.

Received: 22 June 2019 **Accepted:** 23 October 2019 **Citation:** *European Cardiology Review* 2019;14(3):141–50. **DOI:** <https://doi.org/10.15420/ecr.2019.07>

Correspondence: Amelia Carro, Instituto Corvilud, Travesía El Calvario N1, Bajo, 33430 Candás (Asturias), Spain. E: corvilud@gmail.com

Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Dietary Patterns

Several studies correlate healthy dietary patterns with lower plasma concentrations of pro-inflammatory markers.¹ These healthy dietary patterns support greater benefits than the potential effects of a single nutrient supplementation. The current body of evidence shows that healthy dietary patterns share similarities, shown in *Figure 1*.² These features fit with the report of the most recent workshop convened by the World Heart Federation, and three models are recommended by the United States Dietary Guidelines Advisory Committee: Mediterranean diet (MD), American healthy diet and vegetarian diet (VD).^{3,4} The latter is a type of plant-based diet that restricts different types of animal foods (meat, poultry or fish), and has been associated with a lower risk of cardiovascular (CV) risk factors (obesity, hypertension, type 2 diabetes) and coronary heart disease (CHD).^{5,6} However, VD, as a concept, focuses more on the exclusion of animal sources of food than the quality of plant foods; this raises some heterogeneity and deserves further research to assure the features of a heart healthy diet.⁷ Thus, recent studies tried to cluster different subtypes of VD according to the frequency of intake of three food groups: healthy plant foods (whole grains, fruits, vegetables, nuts, legumes, coffee, tea), less healthy plant foods (fruit juices, refined grain, potatoes, sugar sweetened and artificially sweetened beverages, sweets and desserts) and animal foods (animal fat, dairy, eggs, fish or seafood, meat and miscellaneous animal foods) given their associations with chronic conditions.⁸ Diets with higher intake of healthy plant foods and lower in animal foods were associated with a lower risk of incident CV disease (CVD), CVD mortality and all-cause mortality.^{5–7} No true association was found with less healthy plant-based diets and CVD or all-cause mortality.⁷ Therefore, health implications of diets high in refined carbohydrates and sugar, and low in fruits, vegetables and animal foods must be acknowledged when assessing individuals with a VD.

Other therapeutic diets, such as the Dietary Approaches to Stop Hypertension (DASH) and the Portfolio diets recommended in the Canadian Cardiovascular Society guidelines, also emphasise the principles of a healthy diet.^{9,10}

The MD and the DASH diet are probably the best-studied dietary patterns in relation to CVD prevention. Both may improve downregulation of low-grade inflammation and better control of bodyweight, further controlling other risk factors, and ultimately are correlated with lower numbers of clinical events.^{5,11}


Mediterranean Diet

The MD is defined as the traditional dietary pattern found in the early 1960s in Greece, Southern Italy, Spain and other olive-growing countries of the Mediterranean basin.¹² It is a frugal diet that fulfils the definition of “healthy diet” (*Table 1*), with some distinctive attributes (*Figure 1*): olive oil the principal source of fat, moderate intake of wine (mainly wine during meals), fish, seafood, poultry, eggs and dairy products (cheese and yoghurt, preferred in the form of low fat), and low consumption of red meat.

All kinds of olive oil (virgin, extra virgin olive oil and refined olive oil) contain oleic acid as the main fat, but only unrefined olive oil (virgin and extra virgin olive oil) contain tocopherols, phytosterols, monounsaturated fatty acids (MUFA) and several bioactive polyphenols (hydroxytyrosol, tyrosol, oleocanthal, resveratrol), with postulated anti-atherogenic and anti-inflammatory properties.^{13–15}

The evidence supporting CVD benefits is large, strong and consistent, in terms of clinically meaningful rate reductions of CHD, ischaemic stroke and total CVD. Until now, these benefits had been attributed to improvements in blood pressure, lipid profile, glucose metabolism,

Figure 1: Healthy Dietary Pattern



The Mediterranean diet (MD) fulfils basic principles of a “Healthy Dietary Pattern”, with some distinctive features related to the nutrients included (i.e. olive oil, wine), but also extended to other lifestyle choices that are broadly referred as “Mediterranean Lifestyle Pattern”. The graphic represents the MD with food items grouped according to recommended frequency intake. The green boxes show food items that should sustain the diet and provide the highest energy intake (every main meal). Water is included in this section, with a daily recommended intake of 1.5–2.0 l. As well as water, non-sugar-rich herbal infusions and broths (with low-fat and -salt content) may complete the requirements. Orange boxes include foods to be eaten in moderate amounts, such as: protein animal sources: fish (two or more weekly servings), white meat (two weekly servings) and eggs (two to four weekly servings); dairy products: cheese and yoghurt, preferred in the form of low-fat; and alcohol: moderate consumption of wine and other fermented beverages during meals (one glass per day for women and two glasses per day for men, as a generic reference). The red box represents unhealthy fat-rich foods (butter/fat, processed meat) and the sugary (added sugar, refined grains, candies, pastries and sugar-sweetened beverages); SSBs, such as sweetened fruit juices and soft drinks). These should be consumed in small amounts and left for special occasions. Medication is only considered if required for primary or secondary prevention purposes. Lifestyle: along with recommendations regarding the proportion and frequency of food consumption, the MD incorporates lifestyle and cultural elements aimed to acquire all the benefits from the MD, and to preserve the cultural heritage. Blue boxes exemplify mechanisms that confer the MD its ability to reduce cardiovascular risk. These elements embrace moderation, socialisation, culinary activities, physical activity, adequate rest, seasonality, and traditional, local, eco-friendly and biodiverse products. BMI = body mass index; BP = blood pressure; CVD = cardiovascular disease; Glc = glucose; LDL-c = low-density lipoprotein cholesterol; SCFA = short-chain fatty acids; TMAO = trimethylamine N-oxide.

arrhythmic risk or gut microbiome.⁵ However, vascular anti-inflammatory effects have recently been hypothesised as a possible mechanism that links MD and low CVD prevalence (Table 2).^{16–19}

This hypothesis was confirmed by the Prevención con Dieta Mediterránea (PREDIMED) findings on MD mechanisms: modulation of the expression of adhesion molecules in leukocytes; improvements in the circulating levels of soluble adhesion molecules, cytokines, chemokines and macrophage inflammatory proteins; and plaque stabilisation after 3 months, and 1, 3 and 5 years of intervention.²⁰ Epigenetic studies of the MD reinforce these results, with proven influence on the methylation status of peripheral white blood cell genes, interactions among MD and the expression of other molecules (cyclooxygenase-2, interleukin-6, apolipoprotein, cholesteryl ester transfer protein plasma), transcription factors and gene polymorphisms (Table 2).^{21–23}

The authors of the PREDIMED study in 2013 recently retracted the original publication as a result of an error in the randomisation procedures

affecting a portion of participants included.²⁴ The authors re-ran the analyses omitting 1,588 participants from 7,447, and published a corrected version that showed no significant changes in the results of the trial.^{24,25} In both the original and republished study, the incidence of CVD in the MD groups was lowered by approximately 30% when compared with the control diet.^{20,24,25} Therefore, the overall conclusion remains unchanged, and PREDIMED remains the largest dietary intervention trial to assess the effects of the MD on CVD prevention.

Dietary Approaches to Stop Hypertension Diet

The DASH model follows the “healthy diet” pattern (Figure 1), with critical emphasis on a low intake of sodium and refined grains.^{26,27} Focusing on inflammatory markers and oxidative stress, several studies have shown the protective effect of the DASH diet on CVD (Table 1) mediated by significant reductions of high-sensitivity C-reactive protein concentrations. Cross-sectional analysis evaluating potential associations between dietary quality (DASH dietary quality score), adiposity, and biomarkers of glucose metabolism, lipid profile and inflammation reveal that a higher adherence to the DASH dietary pattern significantly improves adiposity measures, and lowers concentrations of pro-inflammatory, pro-thrombotic and pro-atherogenic markers.²⁸ Improvements in lipoprotein profile and glucose homeostasis are also achieved.

It has also been shown that a DASH diet increases plasma renin activity and serum aldosterone levels in response to blood pressure reductions.²⁹ The effect of sodium intake on blood pressure differs by genotype at the angiotensinogen, beta2-adrenergic receptor and kallikrein loci.^{29,30} These findings have implications for understanding the mechanisms through which diet affects blood pressure, the heterogeneity of these effects, and the extent to which dietary and pharmacological interventions can modulate genetic predisposition.^{29,30}

Individual Food Items

There are some specific dietary guidelines that are exclusively food based.^{31–33} Comprehensive dietary modelling is undertaken to ensure nutrient reference values, including targets for sodium, and saturated and trans fat. This section develops some of the features of each of the individual food items and its possible relationship to CVD risk reduction.

Fruits and Vegetables

Daily consumption of multiple servings of both fruits and vegetables is strongly and widely recommended, since its total intake has been inversely associated with CVD risk, and seems to be the healthiest and most beneficial source of anti-oxidants for CVD risk reduction.³⁴ The benefits for subgroups have been less studied, and may vary considerably according to their phytochemical and micronutrient composition (Table 3).^{35–37} Some of the anti-inflammatory mechanisms proposed for fruits and vegetables are summarised in Table 2. Anthocyanins (a subclass of flavonoids) found in blueberries, strawberries, raspberries, red cabbage, red radishes and eggplant have potent anti-inflammatory properties: free radical scavenging, endothelial nitric oxide (NO) regulation, endothelial function modulation and influence on glucose metabolism.^{35–39}

Cruciferous vegetables have been associated with vascular benefits due to their potential to release nitrite via the enterosalivary nitrate–nitrite–NO pathway. Dietary nitrates are secreted by the salivary glands and reduced to nitrite via the action of commensal oral bacteria. Salivary nitrite levels can increase >1,000-fold greater

Table 1: "Healthy Dietary Pattern"

Principles	Main features
Plant-based and high consumption of vegetables, fruits, legumes, nuts, whole grain cereals and fish	Warrant high intake of fibre, anti-oxidants, vitamins, minerals, polyphenols, monounsaturated and polyunsaturated fatty acids
Carbohydrates of low glycaemic load	Keep blood sugar levels consistent, avoiding oscillations in glycaemic levels (and subsequent insulin releases)
Reduced consumption of salt, refined sugar, and saturated and trans fats	Mainly in the form of processed foods, red meats, refined cereals, starches, and sugar-added drinks and foods

Examples of "Healthy Dietary Patterns"

Vegetarian diet*

American healthy diet

Mediterranean diet

Dietary Approaches to Stop Hypertension (DASH)

Portfolio Diet

A healthy dietary pattern fulfils basic principles as detailed. Examples of a "Healthy Dietary Pattern" are given. *Vegetarian Diet focuses on restriction of different types of animal foods and is mainly plant-based; it is important to emphasise, however, that some plant-based food items might include carbohydrates of high glycaemic load (fruit juices, refined grain, potatoes, sugar sweetened and artificially sweetened beverages, sweets and desserts) or even saturated fat. Therefore, it is advisable that plant-based food items of a Vegetarian Diet include a higher proportion of whole grains, fruits, vegetables, nuts, legumes, coffee and tea instead.

Table 2: Proposed Mechanisms for the Anti-inflammatory Effects of Dietary Patterns and Individual Food Items

Dietary Pattern/Food Item	Pro-inflammatory Markers and Genes	Oxidative Stress Markers	Leukocyte Expression
MD ¹⁶⁻²³	sVCAM-1, sICAM-1, RANTES, MIP-1beta, TNF-alpha, TNFR-60, IL-1beta, IL-6, IL-7, IL-10, IL-12p70, IL13, IL-18, MMP-9, VEGF, CRP, TCF7L2, ApoA2, CETP, COX-2, MCP-1, LRP1	Lymphocytes: CD11a, CD49d, CD40 Monocytes: CD11a, CD11b, CD49d, CD40	MDA, oxLDL
DASH diet ²⁸	sICAM-1, IL-6, CRP, PAI-1		
Fruits, ^{35,38,39} vegetables, ^{35,38,39} legumes ^{48,49}	TNF-alpha, TNFR-60, IL-1beta, IL4, IL-6, gamma delta T cell, fibrinogen, sE-selectin		F2-isoprostanes, 2,3 dinor-5,6-dihydro-15-F2t IsoP
Nuts ^{50,55-57}	CRP, IL-6, TNF-alpha, TNF-beta, TNF-R2, sICAM-1, fibrinogen, PF4, resistin		
Fermented beverages ⁷⁵⁻⁷⁹	IL-1-alpha, IL-5, IL-6, IL-6r, IL-8, IL-10, IL-15, IL-18, CRP, MDC, sVCAM-1, sICAM-1, E selectin, fibrinogen, CD40 ligand, MCP-1, factor VII, PAI-1, IFN-gamma, RANTES, TNF-beta	Lymphocytes: LFA-1 monocytes: LFA-1, MAC-1, VLA-4, CCR2, CD36, CD15	SOD, MDA
Coffee ^{92,94} and tea ⁹⁵⁻⁹⁸ (polyphenols)	NF-kappa beta, sICAM-1, sE- and sP-selectin, IL-1beta, IL-18, CRP, SAA, CXCL5, CXCL7, CXCL8, CXCL12, CCL2, TNF-alpha, beta-thromboglobulin, RANTES, ApoB	Monocytes: VLA-4, CD40, CD36	oxLDL, 8-iso-prostaglandin F2-alpha, ROS, SOD, Nrf2
Omega-3 PUFA ¹²⁵⁻¹²⁷	sVCAM-1, sICAM-1, sP-selectin, TNF-alpha, TNFR, IL-1beta, IL-6, MMP-7, MMP-9, CRP, PAI-1, SAA		T-lymphocytes
Fibre ¹⁹	sVCAM-1, sICAM-1, TNF-alpha, TNFR2, IL-6, IL-18, CRP, PAI-1		
Anti-oxidants/vitamins ^{153,154}	IL-6, CRP, TNF-alpha, leptin, tHcy		
Polyphenol ^{92,94-98}	NF-kappa beta, sICAM-1, sE- and sP-selectin, IL-1beta, IL-18, CRP, SAA, CXCL5, CXCL7, CXCL8, CXCL12, CCL2, TNF-alpha, beta-thromboglobulin, RANTES, ApoB	Monocytes: VLA-4, CD40, CD36	oxLDL, 8-iso-prostaglandin F2alpha, ROS, SOD, Nrf2

ApoA2 = apolipoprotein A2; ApoB = apolipoprotein B; CCL2 = chemokine (C-C motif) ligand 2; CETP = cholesteryl ester transfer protein plasma; COX-2 = cyclooxygenase-2; CRP = C-reactive protein; CXCL = chemokine (C-X-C motif) ligand; DASH = Dietary Approaches to Stop Hypertension; LFA = lymphocyte function-associated antigen 1; IL = Interleukin; LRP1 = low-density lipoprotein receptor-related protein; MDC = macrophage-derived chemokine; MCP-1 = monocyte chemoattractant protein; MD = Mediterranean diet; MDA = malondialdehyde; oxLDL = oxidised LDL; MIP-1beta = macrophage inflammatory protein 1 beta; MMP-9 = metalloproteinase-9; Nrf2 = nuclear factor (erythroid-derived 2)-like 2; omega-3 PUFA = omega-3 polyunsaturated fatty acid; PAI-1 = plasminogen activator inhibitor 1; PF4 = platelet factor 4; RANTES = regulated on activation; SAA = serum amyloid A; sICAM-1 = soluble intercellular adhesion molecule 1; SOD = superoxide dismutase; sVCAM-1 = soluble vascular cell adhesion molecule; TCF7L2 = transcription factor 7-like 2; tHcy = total homocysteine; TNF = tumour necrosis factor; TNFR = tumour necrosis factor receptor; VEGF = vascular endothelial growth factor; VLA-4 = very late antigen-4.

than in the circulation.⁴⁰ Among leafy green vegetables, nitrate concentrations are most appreciable in spinach, arugula, mesclun, lettuce and Swiss chard.^{41,42} The European Food Safety Authority has set the Acceptable Daily Intake for nitrate at 3.7 mg/kg (approximately 260 mg for a 70-kg adult).⁴¹ A recently published systematic review and meta-analysis reported that intakes of dietary nitrate were significantly associated with a reduction in resting blood pressure,

improved endothelial function, reduced arterial stiffness and reduced platelet aggregation.⁴³

The amount of vegetable intake recommended in dietary guidelines varies globally, but is usually around five or six servings/day (375–450 g/day). For vegetable types, leafy green vegetables, cruciferous vegetables and tomatoes were inversely associated with CVD risk

Table 3: Classification of Vegetable Types with Nutrients and Phytochemicals Associated with Each Vegetable Type^{35–37,39}

Vegetable classification					
Cruciferous	Leafy green	Yellow-orange-red	Purple vegetables	Allium	Legumes
<ul style="list-style-type: none"> • Cabbage • Cauliflower • Broccoli • Brussels sprouts • Red cabbage • Red radishes • Collard greens • Kale 	<ul style="list-style-type: none"> • Lettuce • Spinach • Arugula • Mesclun • Swiss chard • Celery 	<ul style="list-style-type: none"> • Tomato • Carrot • Pumpkin • Sweet potato • Yellow capsicum • Red capsicum 	<ul style="list-style-type: none"> • Red cabbage • Red radishes • Eggplant 	<ul style="list-style-type: none"> • Onion • Garlic • Leek 	<ul style="list-style-type: none"> • Lentils • Peas • Chickpeas • Kidney beans • Soybeans • Green beans
<ul style="list-style-type: none"> • Organosulfur compounds (isothiocyanates, glucosinolates) • Vitamin E (tocopherols) • Vitamin C • Carotenoids (lutein, zeaxanthin, beta-carotene) • Flavanols (quercetin, isorhamnetin, kaempferol) • Flavanones (naringenin) • Selenium • Calcium 	<ul style="list-style-type: none"> • Nitrate • Vitamin K (phyloquinone) • Vitamin E (alpha-tocopherol) • Vitamin C • Carotenoids (lutein, beta-carotene) • Flavanols (quercetin, isorhamnetin, kaempferol) • Folate • Iron • Zinc • Calcium 	<ul style="list-style-type: none"> • Carotenoids (lycopene, alpha-carotene, beta-carotene, beta-cryptoxanthin) 	<ul style="list-style-type: none"> • Flavanols (quercetin) • Folate (vitamin B9) • Carotenoids (vulgaxanthin) • Manganese • Potassium • Iron • Vitamin C 	<ul style="list-style-type: none"> • Organosulfur compounds (allin, methiin, propiin, isoalliin, allicin) • Flavanols (quercetin, isorhamnetin, kaempferol) • Selenium 	<ul style="list-style-type: none"> • Isoflavones • Saponins • Flavanols (quercetin) • Folate • Iron • Zinc • Calcium • Dietary fibre • Vitamin E • Vitamin B6 • Selenium • Lignans

in non-linear dose–response analyses. The greatest CVD benefits were observed at intakes of ≥ 200 g/day for cruciferous vegetable, ≥ 120 g/day for leafy green vegetables and ≥ 200 g/day for tomatoes.⁴⁴

Daily recommendations on fruit intake range from 100 to 300 g (200 g/day). However, it must be taken in to account that the process of juicing concentrates calories, risking excess energy intake and loss of fibre. There are few studies evaluating the clinical benefits of vegetable juicing versus raw or cooked forms. Until comparative data become available, whole food consumption is preferred, with juicing primarily reserved for situations when daily intake of vegetables and fruits is inadequate. Guidance should be provided to maintain optimal overall caloric intake and to avoid the addition of sugars (e.g. honey) to minimise caloric overconsumption. In addition, there is no evidence of CV benefit with the addition of high-dose antioxidant dietary supplements if these intakes are warranted.

Legumes

Legumes are seeds with complex matrices rich in nutrients and chemicals, carrying a high caloric density that makes them an affordable and sustainable source of protein and fibre. Various effects on CV risk factors provide evidence for CV prevention. These foods have a low glycaemic index, and reduce glycaemia and postprandial insulinaemia, favouring diabetes prevention, especially in the context of a MD.⁴⁵ Legumes have a hypocholesterolaemic effect (lowering both LDL and triglycerides), but their presumed effect in reducing blood pressure has not been consistently proven.^{46,47}

Legumes are a good source of protein, starch, isoflavones, vitamin B₆, folate and iron. The anti-inflammatory effects of this food group are frequently included with vegetables, which makes it difficult to separate its own mechanisms on pro-inflammatory/oxidative stress markers and leukocyte expression (Table 2). However, significant reductions of high-sensitivity C-reactive protein, interleukin-6 and tumour necrosis factor-alpha with a legume-based diet have been demonstrated, independent of caloric intake or weight change.^{48,49}

Based on these beneficial properties, legumes should be part of any cardiometabolic healthy diet, with a daily intake of around 50–100 g (140–180 kcal/day).⁵⁰

Nuts and Seeds

Nuts and seeds (almonds, hazelnuts, walnuts, pistachios, cashews, macadamias, pinions, peanuts etc.) are peculiar vegetables with a high fat content (usually exceeding 50% of energy) mainly containing unsaturated fatty acids (UFA), such as oleic MUFA (almonds, hazelnuts) or n-6 polyunsaturated linoleic and n-3 as alpha-linolenic acid (in nuts). Although peanuts are actually vegetables, their composition and UFA content assimilates them to nuts. Nuts and seeds contain other bioactive compounds: L-arginine, soluble fibre, vitamin E, phytosterols, polyphenols, anti-oxidants, potassium, calcium and magnesium. Numerous large prospective cohort studies have demonstrated reductions in CVD morbidity and mortality with the consumption of nuts and seeds.^{51,52} Mechanisms proposed for favourable CVD outcomes are likely mediated by dose-dependent hypocholesterolaemic effects and improvements of glycaemic profile.^{53,54} The PREDIMED study provided first-class evidence that regular nut consumption halves the incidence of diabetes, and reduces the incidence of CVD by 30%.²⁰ Additional benefits are derived from the role on oxidative stress, inflammation and vascular reactivity through modulation of inflammatory and oxidants mediators (Table 2).^{20,55–57}

Although the benefits are accepted, there is no standard recommendation for nuts inclusion on dietary patterns. Following a MD, daily supplementation with a serving of mixed nuts (i.e. 15 g walnuts, 7.5 g almonds and 7.5 g hazelnuts) would be enough to get the desired CV effects. Caution must be taken at >75 g, because of the risk of excess caloric intake.

Grains and Tubers

Grains are the largest source of energy in almost all diets worldwide. The bran and germ layers present in whole grains are rich in fibre, lignans, micronutrients, fatty acids and other phytonutrients.⁵⁸

Depletion of these nutrients during the milling process partially explains why whole grain consumption is generally related to higher satiety and a lower glycaemic response compared with refined grains.⁵⁹ High intake of whole grains has been associated with reduced risk of CHD disease, type 2 diabetes and overall mortality.⁶⁰ Refining grains, in contrast, causes major loss of nutrients and fibre, which has important health implications, including adverse metabolic effects, weight gain, increased risk of CVD and overall mortality.^{60–62}

There are few data linking gluten and CHD. People with coeliac disease or gluten sensitivity might have inflammatory mechanisms more related to zonulin release into the gut than to gliadin, and these altered pathways could predispose to type 2 diabetes and even CHD.^{63,64} However, there is no current evidence supporting a link between gluten consumption and CHD, and should not be restricted in people without coeliac disease or gluten sensitivity.⁶⁵

Roots and tubers (the so-called starchy vegetables) are a good source of starch, which may help maintain a healthy gut.⁶⁶ Gut dysbiosis is associated with intestinal inflammation and has been linked to the development of CVD.⁶⁷ However, there is no evidence that restoring gut dysbiosis with tubers improves CV outcomes. Intake of potatoes, for instance, provides a large amount of rapidly absorbed carbohydrate (glycaemic load), and its daily consumption has been associated with increased risk of type 2 diabetes, hypertension, weight gain and even CHD (especially consumed in the form of “French fries”).^{68–71}

Evidence does not support strong recommendations on the specific proportion of energy intake from carbohydrates, but keeping this to <60% of energy appears desirable, and consumption of whole grains is emphasised. This would be about 232 g/day of whole grains, and 50 g/day of tubers and starchy vegetables (with a limit of 100 g/day of tubers and starchy vegetables).

Fish and Seafood

Fish intake has been associated with reduced risk of CVD, mainly attributed to the particular properties of omega-3 fatty acids (O3FA), which are abundant in fish composition.^{72,73} O3FA are precursors of eicosanoids, a large component of the central nervous system, a structural element of every cell of the body and a regulator of cardiac rhythm. They are thought to reduce arrhythmias, thrombosis, inflammation and blood pressure, and favourably modify the lipid profile.⁷⁴ An average weekly intake of 2 g of O3FA in fish might reduce CVD risk by more than one-third.⁷² Although O3FA from plant sources (specifically alpha-linolenic acid) have been associated with reduced risk of CVD disease and had been proposed as an alternative source to substitute fish, the quantity required is not clear.

Beverages

Alcohol

Alcoholic beverages contain ethanol (ethyl alcohol) and are classified by the elaboration process as: fermented (by alcohol fermentation; <15% alcohol content): red or white wine, beer or cider; and distillate (by alcohol distillation; 20–60% alcohol content): spirits, such as cognac, whiskey, gin, vodka and rum, and liqueurs flavoured with fruits, herbs or spices.

Fermented beverages are believed to provide a greater CV protection than distillate beverages, especially red wine. Its higher polyphenol content favourably modifies oxidation and inflammation parameters

related to arteriosclerosis by different pathways: higher NO availability (improving endothelial function), increases in HDL cholesterol levels and anti-aggregation/profibrinolytic/anti-inflammation properties (*Table 2*).^{75–79} Beer is another type of fermented beverage with moderate polyphenol content that has cardioprotective effects comparable to wine.^{80,81} Both alcoholic and non-alcoholic beer improve inflammatory biomarkers profile, homocysteine and folic acid levels (*Table 2*).

Alcohol intake and CVD risk show a “U-shaped” relationship, with both abstainers and heavy drinkers carrying a higher risk than moderate drinkers.^{82,83} Adverse effects of (often heavy) alcohol consumption include a higher risk of atrial fibrillation, non-ischaemic dilated cardiomyopathy and long-term weight gain.^{84–86} In addition, alcohol is causally linked to upper aerodigestive tract cancers (oral cavity, pharynx, larynx, oesophagus), and those of the colon, liver and female breast. Associations exist for many other types of cancer, but the precise role of alcohol requires further research for it to be fully disentangled from ecological and lifestyle factors.⁸⁷

By definition, a standard drink contains 14 g of ethanol (17 g of pure alcohol). This equates to 350 ml of beer (5% ethanol), 150 ml of table wine (12% ethanol), or 45 ml of hard liquor or distilled spirits (40% ethanol).⁸⁸ Although the exact nadir of risk depends on sex, age, ethnicity and baseline disease, it seems that consuming one or two daily drinks derives the lowest risk (2 for men; 1–1.5 for women).^{89,90} This would be the daily intake recommendation, mainly in the form of fermented beverages.

Coffee

Coffee is one of the most widely consumed beverages in the world, representing the liquid extract of coffee beans. It contains many active compounds responsible for its bitter taste, and conferring anti-oxidant and anti-inflammatory actions.

Several mechanisms contribute to the sustained CV health effects of coffee. However, the response of each individual component varies, and might interfere with others in a complex relationship. Various genetic polymorphisms affecting caffeine metabolism (i.e. cytochrome P450 1A2 variants), receptor-mediated effects (i.e. adenosine receptors) or non-receptor mediated effects (e.g. low catechol-O-methyltransferase activity) may influence an individual’s response to caffeine. An increased risk of CHD or MI has been reported only among individuals with a genotype associated with slow caffeine metabolism (CYP1A2*1F instead of CYP1A2*1A), or low catechol-O-methyltransferase activity genotype (low catecholamine metabolism).⁹¹ The infusion of coffee maintains a high concentration of potassium, magnesium, vitamin E, niacin, polyphenols (mainly chlorogenic acid), micronutrients, lignans and phytochemicals. Chlorogenic and caffeic acids improve the anti-oxidative status of the body by slowing down the process of inflammation, which protects from the hazardous effect of free radicals and against endothelial damage. There is no scientific association with blood pressure elevation and, in turn, it actually lowers diabetes risk in a dose-dependent manner.⁹²

Unlike filtered coffee, some components present in unfiltered coffee (cafestol and kahweol) raise serum lipids.⁹³ Whether these components are involved in the deposition of LDL cholesterol is still debated. Usually, consumption of three or four daily cups of coffee leads to a small increase in HDL cholesterol. The effect on LDL is more complex, since the resistance of LDL to oxidative modification increments significantly after drinking coffee, but the LDL concentration does not (or at least,

not significantly).⁹⁴ Therefore, regular consumption of coffee (3–5 cups/day, which corresponds to a coffee polyphenol intake of 101–337 mg/day) can be recommended based on its ability to lower CVD risk.⁹³

Tea

Tea contains a significant amount of flavonoids and polyphenols, considered the most abundant dietary anti-oxidants present, and responsible for a wide range of health effects in the prevention of CVD.⁹⁵ Polyphenols delay progression of atherosclerosis through several mechanisms: regulation of signalling–transcription pathways (including downregulation of pro-inflammatory cytokines) and anti-oxidant systems (enhanced NO production), prevention of leukocyte migration/plaque infiltration, and reduction of adhesion molecules, among others (Table 2).⁹⁶ Both short- and long-term tea consumption have shown to improve endothelium-dependent flow-mediated dilation, reverse endothelial vasomotor dysfunction in CHD patients and are associated with favourable changes on lipid profile.^{97–99} These effects translate into a lower risk of developing CHD and major cardiac events, even all-cause mortality.^{100,101}

The evidence for a favourable CVD profile is based on regular tea consumption (3–5 cups/day) without added sugars, sweeteners or milks and creams (both animal and plant-based), and that should be the proper way to tackle any recommendation on this beverage.

Dairy Products

A growing body of nutritional science highlights the complex mechanisms and pleiotropic pathways of cardiometabolic effects of dairy products (i.e. milk, yogurt and cheese) that may be mediated by specific proteins (whey and casein proteins), amino acids (leucine, isoleucine and valine), medium-chain and odd-chain saturated fats, UFA, branched-chain fats, natural trans fats, probiotics, vitamin K₁/K₂, and calcium, or by processing methods (fermentation/homogenisation). These intricate processes translate into divergent conclusions regarding CVD: although systematic reviews and meta-analyses show either neutral or a favourable association between dairy intake and CVD-related outcomes, other studies associate dairy fat with a unfavourable risk profile that can be reversed by replacing fat from dairy products with polyunsaturated fatty acid (PUFA) or vegetable fat.^{102–108} In cohorts utilising objective biomarkers, higher blood levels of dairy fatty acids are consistently associated with a lower incidence of diabetes and neutral/favourable CVD risk profile. Reduced fat dairy products remain a convenient source of some essential vitamins and minerals, and high-quality protein. Obtaining these compounds should not be routinely based on supplements, since fermentation processes and probiotics are a relevant component in the biological pathways and clinical effects of these foods.¹⁰⁹ In fact, the VITamin D and Omega-3 Trial (VITAL) trial has recently shown that diet supplementation with non-dietary vitamin D did not result in a lower incidence of invasive cancer or CV events than a placebo, which highlights the relevance of metabolic pathways in the effects observed with dairy products.¹¹⁰

Although further investigation is required, based on available evidence, the empiric recommendation on reduced-fat in place of regular- and high-fat dairy is adequate, and is included in MD and DASH dietary patterns (average 250 mg/daily, yielding 150 kcal of caloric intake).

Eggs

The high cholesterol concentrations found in eggs (200–230 mg/egg; 350–385 mg/100 g) led to the widespread recommendation of

limiting egg intake in fear of subsequent increases in total and LDL cholesterol.¹¹¹ However, eggs are rich in amino acids and several micronutrients that might interplay for the net effect on cholesterol levels and its clinical impact. Clinical studies reveal that cholesterol increases are discrete, with interindividual variability, and are coupled with slight elevations in HDL cholesterol that favour the development of large and low-atherogenic LDL particles.¹¹² In fact, even daily egg consumption is not clearly associated with incident CVD in general populations and might reduce stroke risk.^{113–115}

However, US dietary guidelines raised controversy because of apparently contradictory statements, saying that ‘cholesterol is not a nutrient of concern for overconsumption’, but that ‘individuals should eat as little dietary cholesterol as possible’.⁷

A recent study involving pooled individual data from six prospective US cohorts found that egg consumption was associated with an increased incidence of CVD and death.¹¹⁶ However, the association was possibly biased and inaccurately proven. A recent meta-analysis and systematic review found no association between egg intake and CHD or total mortality, but, in contrast, lower risk of mortality from stroke.¹¹⁷ Egg consumption has been also associated with hypertension, type 2 diabetes and markers of glucose homeostasis.^{117,118}

The debate on the role of eggs for CVD prevention would remain largely moot until further data (including the genetic basis of cholesterol intake on CVD risk) are clearly defined. In the meantime, the importance of following evidence-based dietary recommendations, such as limiting intake of cholesterol-rich foods, should not be dismissed. Cardiometabolic effects can be derived from the consumption of up to two or three eggs per week, even in people with diabetes.

Oils, Butter and Fats

Primary types of dietary fat include saturated fat (SFA), UFA (including MUFA and PUFA) and trans fatty acids. Only dietary trans fatty acids intake demonstrates a consistent and strong association with adverse CVD outcomes. SFA have received widespread controversy, as the increases of total and LDL cholesterol levels undoubtedly translate into either neutral or harmful CVD outcomes in different clinical trials and meta-analyses.^{119–122} It must be acknowledged that SFA are diverse compounds with variable effects on CHD risk depending on many factors apart from the dietary SFA intake, such as the SFA status, biomarkers and the carbon length of the SFA.¹²³ Genetic factors contribute to the risk of CHD related to the dietary intake of C-18 fatty acid. It is advisable to replace long-chain fatty acids (LCFA) with PUFA, MUFA, short-chain fatty acids, whole grains and plant proteins.^{123,124}

Mechanisms for the benefit with long-chain O3FA derived from fish oil might include improvements in the lipid and lipoprotein profile, oxidation, thrombosis, platelet aggregation, endothelial function, blood viscosity, membrane fluidity and plaque stability, modulation of concentration/expression of pro-inflammatory markers (adhesion molecules, cytokines etc.), and immune cells (Table 2).^{125–127}

Noteworthy, benefits of the supplementation with these fatty acids remain to be confirmed.^{128,129} Although icosapent ethyl administration in patients with elevated triglyceride demonstrated significant reduction in CVD outcomes, the addition of O3FA did not result in a lower incidence of major CV events or cancer than placebo

in a primary prevention trial.^{110,130} In addition, it is not possible to recommend the safest amount of dietary consumption of SFA, especially LCFA, at this time, but studies suggest it should be well below 9% of total caloric intake.¹²³

Coconut oil is 92% SFA, predominantly lauric acid C12:0 and myristic acid (C14:0). Since only 4% of coconut oil has short-chain fatty acids (C-10 or less fatty acids), it acts mostly as a LCFA, with direct portal vein absorption and is highly soluble in water.¹³¹ However, there is a lack of prospective studies on CV, and the current literature raises mixed effects on serum lipids and the content of LCFA. In addition, replacement of coconut oil with PUFA and MUFA seems to reduce CHD risk.⁶⁴ Therefore, this yet scarce evidence does not currently support coconut oil use for the prevention or treatment of CVD, and general recommendations on SFA intake (limited to <9% of total energy intake) should prevail.^{7,123}

Meat

The intake of meat has increased in industrialised countries, and actually constitutes the basic component of meals. Although general meat consumption has been reported to be associated with all-cause and specific-cause mortality, the type of meat considered (red, white, processed) might redefine these associations. Red meat and processed meat may increase the risk of all-cause and CV mortality by means of several components that boost CV alterations.^{132,133} Various red meat-associated agents have been invoked, including SFA, high salt intake, trimethylamine N-oxide generation by microbiota and environmental pollutants contaminating red meat, none of which are specific to red meat. For instance, it has been demonstrated that residues of organochlorine pesticides are present in red meat at concentrations close to the WHO maximum recommendations. Epidemiological evidence and systematic reviews support an association of pesticide exposure with CVD and CV mortality (MI, cerebrovascular disease). These associations might be mediated via oxidative stress and inflammation pathways.¹³⁴

Other human-specific hypotheses associated with red meat are also plausible, such as infectious agents (viruses) or xenoautoantigens (triggered by metabolic incorporation of a non-human sialic acid N-glycolylneuraminic acid into the tissues of red meat consumers).¹³³ N-glycolylneuraminic acid incorporation from red meat can induce xenosialitis in vascular endothelium, and may contribute to red meat-induced aggravation of atherosclerosis and CVD. Despite all this circumstantial evidence, further research is required to confirm that this process is actually pro-atherogenic *in vivo* and thus a major causative factor in the development of CVD in humans.¹³⁴

Very little has been reported about the impact of white meat intake on health; the interpretation of such effects is an arduous task, as individuals consuming more white meat are, at the same time, consuming less red meat. Findings obtained from meta-analyses are weak, and do not report increments on all-cause or CV mortality with 100 g daily consumption.^{135,136} Therefore, this could be a reasonable recommendation until more studies assessing the effect of white meat consumption on mortality are conducted, and there is no current evidence to support the choice of white over red meat in terms of CV risk reduction.

Added Sugar and Sugar-sweetened Beverages

The first associations between excess intake of added sugars,

metabolic abnormalities and CV risk surfaced in the 1950s, but were eclipsed until recently (2014) by the belief that an excess intake of SFA was the key dietary factor.

Sweeteners are mainly being consumed as sugar substitutes that can be classified as nutritive sweeteners (polyols or sugar alcohols) and non-nutritive substitutes. Although almost 75% of packaged foods contain added sugars, sugar-sweetened beverages (SSBs; soda, sweet teas, fruit drinks) account for half of all added sugar intake.^{137–139} The effects of non-nutritive substitutes, both artificial sweeteners (acesulfame K, aspartame, cyclamate, saccharin, neotame, advantame and sucralose) and natural sweeteners (NSSs; thaumatin, steviol glycosides, monellin, neohesperidin dihydrochalcone and glycyrrhizin) are conflicting.¹⁴⁰ NSSs interfere with glucose and energy homeostasis; alter leptin levels; adversely modify lipid profile, inflammatory factors, circulation and composition of gut microbiota; and decrease satiety, consequently increasing the risk of CHD, MI, cerebrovascular accident and vascular death.^{64,137,140–146}

While some studies report an association between NSS use and reduced risk of overweight, obesity and type 2 diabetes, other studies suggest that NSS use could increase all of them, and the risk of metabolic syndrome, CHD and cancer.⁶⁴ This association might be influenced by gene–SSB interactions.¹³⁷ In particular, intake of SSBs can exacerbate the effects of chromosome 9p21 variants (i.e. rs4977574), considered the most robust genetic markers on CHD.¹⁴⁷ The clinical and epidemiological data available at present are insufficient to make definitive conclusions regarding the benefits of non-nutritive substitutes in displacing caloric sweeteners as related to energy balance, maintenance or decrease in bodyweight and other cardiometabolic risk factors.

Based on the previously mentioned evidence, numerous expert bodies have now made recommendations to limit dietary added sugar intake to <10% of calories, and preferably <100 calories daily for women and <150 calories daily for men. Clinicians should recommend careful selection of foods with no or low amounts of added sugars in any form, and elimination of SSB. Patients should also be taught how to read nutrition labelling for added sugars.^{148,149}

Other Nutrients and Bioactive Compounds

It is important to focus on the potential benefits of the intake of specific nutrients to avoid possible deficiencies of these nutrients, which can lead to the development of atherosclerotic disease.

Fibre

The health benefits of dietary fibre intake are indisputable, while a deficiency of fibre intake is associated with CVD development.¹⁵⁰ The implicated mechanisms include decreased glucose/cholesterol absorption, downregulation of expression of oxidative stress-related cytokines or the inflammatory response mediated by gut microbiota exposed to fibre.¹⁹ The influence of long-term fibre intake on gut microbiota responsiveness to specific interventions is now becoming apparent. Increased fibre intake has been shown to improve certain metabolic parameters associated with obesity and its comorbidities (glucose homeostasis, serum cholesterol levels, blood pressure), particularly in conjunction with energy-controlled dietary regimes.¹⁵¹ The association between dietary fibre intake and risk of CHD has been studied through meta-analysis showing a significant dose–response relationship, especially for fibre from cereals and fruits.¹⁵²

- PMID: 25833969.
113. Shin JY, Xun P, Nakamura Y, et al. Egg consumption in relation to risk of cardiovascular disease and diabetes: a systematic review and meta-analysis. *Am J Clin Nutr* 2013; 98:146–59. <https://doi.org/10.3945/ajcn.112.051318>; PMID: 23676423.
 114. Rong Y, Chen L, Zhu T, et al. Egg consumption and risk of coronary heart disease and stroke: dose response meta-analysis of prospective cohort studies. *BMJ* 2013;346:e8539. <https://doi.org/10.1136/bmj.e8539>; PMID: 23295181.
 115. Alexander DD, Miller PE, Vargas AJ, et al. Meta-analysis of egg consumption and risk of coronary heart disease and stroke. *J Am Coll Nutr* 2016;35:704–16. <https://doi.org/10.1080/07315724.2016.1152928>; PMID: 27710205.
 116. Zhong VW, Van Horn L, Cornelis MC, et al. Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality. *JAMA* 2019;321:1081–95. <https://doi.org/10.1001/jama.2018.15246>; PMID: 30874756.
 117. Mazidi M, Katsiki N, Mikhailidis DP, et al. Egg Consumption and Risk of Total and Cause-Specific Mortality: An Individual-Based Cohort Study and Pooling Prospective Studies on Behalf of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. *J Am Coll Nutr* 2019;38:552–63. <https://doi.org/10.1080/07315724.2018.1534620>; PMID: 31173548.
 118. Way X, Son M, Meram C, et al. Mechanism and Potential of Egg Consumption and Egg Bioactive Components on Type-2 Diabetes. *Nutrients* 2019;11: 357. <https://doi.org/10.3390/nu11020357>; PMID: 30744071.
 119. Astrup A, Dyerberg J, Elwood P, et al. The role of reducing intakes of saturated fat in the preventions of cardiovascular disease. Where does the evidence stand in 2010? *Am J Clin Nutr* 2011; 93:684–8. <https://doi.org/10.3945/ajcn.110.004622>; PMID: 21270379.
 120. Chowdhury R, Warnakula S, Kunutsor S, et al. Association of dietary, circulating and supplement fatty acids with coronary risk: a systematic review and meta-analysis. *Ann Intern Med* 2014;160:398–406. <https://doi.org/10.7326/M13-1788>; PMID: 24723079.
 121. Siri-Tarino PW, Sun Q, Hu FB, et al. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. *Am J Clin Nutr* 2010;91:502–9. <https://doi.org/10.3945/ajcn.2009.27725>; PMID: 20071648.
 122. Bier DM. Saturated Fats and Cardiovascular Disease: Interpretations Not as Simple as They Once Were. *Crit Rev Food Sci Nutr* 2016;56:1943–6. <https://doi.org/10.1080/10408398.2014.998332>; PMID: 25774535.
 123. Houston MC. The Role of Saturated Fats in Coronary Heart Disease. *J Heart Stroke* 2017;2:1025–6.
 124. Mente A, Dehghan M, Rangarajan S, et al. Prospective Urban Rural Epidemiology (PURE) study investigators. Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study. *Lancet Diabetes Endocrinol* 2017;5:774–87. [https://doi.org/10.1016/S2213-8587\(17\)30283-8](https://doi.org/10.1016/S2213-8587(17)30283-8); PMID: 28864143.
 125. Calder PC. The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. *Mol Nutr Food Res* 2012;56:1073–80. <https://doi.org/10.1002/mnfr.201100710>; PMID: 22760980.
 126. Fredman G, Tabas I. Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. *Am J Pathol* 2017;187:1211–21. <https://doi.org/10.1016/j.ajpath.2017.01.018>; PMID: 28527709.
 127. Bennett M, Gilroy DW. Lipid Mediators in Inflammation. *Microbiol Spectr* 2016;4. <https://doi.org/10.1128/microbiolspec.MCHD-0035-2016>; PMID: 27837747.
 128. Aung T, Halsey J, Kromhout D, et al. Omega-3 Treatment Trialists' Collaboration. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. *JAMA Cardiol* 2018;3:225–34. <https://doi.org/10.1001/jamacardio.2017.5205>; PMID: 29387889.
 129. Siscovick DS, Barringer TA, Fretts AM, et al. Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease. A science advisory from the American Heart Association. *Circulation* 2017;135:e867–84. <https://doi.org/10.1161/CIR.0000000000000482>; PMID: 28289069.
 130. Bhatt DL, Steg PG, Miller M, et al. REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *New Eng J Med* 2019;380:11–22. <https://doi.org/10.1056/NEJMoa1812792>; PMID: 30415628.
 131. Wallace TC. Health Effects of Coconut Oil-A Narrative Review of Current Evidence. *J Am Coll Nutr* 2019;38:97–107. <https://doi.org/10.1080/07315724.2018.1497562>; PMID: 30395784.
 132. Micha R, Wallace SK, Mozaffarian D. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. *Circulation* 2010;121:2271–83. <https://doi.org/10.1161/CIRCULATIONAHA.109.924977>; PMID: 20479151.
 133. Alisson-Silva F, Kawanishi K, Varki A. Human risk of diseases associated with red meat intake: Analysis of current theories and proposed role for metabolic incorporation of a non-human sialic acid. *Mol Aspects Med* 2016;51:16–30. <https://doi.org/10.1016/j.mam.2016.07.002>; PMID: 27421909.
 134. Mostafalou S, Abdollahi M. Pesticides: an update of human exposure and toxicity. *Arch Toxicol* 2017;91:549–99. <https://doi.org/10.1007/s00204-016-1849-x>; PMID: 27722929.
 135. Abete I, Romaguera D, Vieira AR, et al. Association between total, processed, red and white meat consumption and all-cause, CVD and IHD mortality: a meta analysis of cohort studies. *Br J Nutr* 2014;112:762–75. <https://doi.org/10.1017/S000711451400124X>; PMID: 24932617.
 136. Bergeron N, Chiu S, Williams PT, et al. Effects of red meat, white meat, and nonmeat protein sources on atherogenic lipoprotein measures in the context of low compared with high saturated fat intake: a randomized controlled trial. *Am J Clin Nutr* 2019;pii:nqz035. <https://doi.org/10.1093/ajcn/nqz035>; PMID: 31161217; epub ahead of press.
 137. Malik VS, Hu FB. Sugar-Sweetened Beverages and Cardiometabolic Health: An Update of the Evidence. *Nutrients* 2019;11:pii:E1840. <https://doi.org/10.3390/nu11081840>; PMID: 31398911.
 138. Bray GA, Popkin BM. Dietary sugar and body weight: have we reached a crisis in the epidemic of obesity and diabetes? Health be damned! Pour on the sugar. *Diabetes Care* 2014;37:950–6. <https://doi.org/10.2337/dc13-2085>; PMID: 24652725.
 139. James P, Seward MW, James O'Malley A, et al. Changes in the food environment over time: examining 40 years of data in the Framingham Heart Study. *Int J Behav Nutr Phys Act* 2017;14:84. <https://doi.org/10.1186/s12966-017-0537-4>; PMID: 28646894.
 140. Toews I, Lohner S, Küllenberg de Gaudry D, et al. Association between intake of non-sugar sweeteners and health outcomes: systematic review and meta-analyses of randomised and non-randomised controlled trials and observational studies. *BMJ* 2019;364:k4718. <https://doi.org/10.1136/bmj.k4718>; PMID: 30602577.
 141. de Koning L, Malik VS, Kellogg MD, et al. Sweetened beverage consumption, incident coronary heart disease, and biomarkers of risk in men. *Circulation* 2012;125 Suppl:1735–41. <https://doi.org/10.1161/CIRCULATIONAHA.111.067017>; PMID: 22412070.
 142. Ruiz-Ojeda FJ, Plaza-Díaz J, Sáez-Lara MJ, et al. Effects of Sweeteners on the Gut Microbiota: A Review of Experimental Studies and Clinical Trials. *Adv Nutr* 2019;10 Suppl:S31–S48. <https://doi.org/10.1093/advances/nmy037>; PMID: 30721958.
 143. Azad MB, Abou-Setta AM, Bhupendrasinh F, et al. Nonnutritive sweeteners and cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials and prospective cohort studies. *CMAJ* 2017; 189:E929–E939. <https://doi.org/10.1503/cmaj.161390>; PMID: 28716847.
 144. Mossavar-Rahmani Y, Kamensky V, Manson JE, et al. Artificially Sweetened Beverages and Stroke, Coronary Heart Disease, and All-Cause Mortality in the Women's Health Initiative. *Stroke* 2019;50:555–62. <https://doi.org/10.1161/STROKEAHA.118.023100>; PMID: 30802187.
 145. Pase MP, Himali JJ, Beiser AS, et al. Sugar- and Artificially Sweetened Beverages and the Risks of Incident Stroke and Dementia: A Prospective Cohort Study. *Stroke* 2017;48:1139–46. <https://doi.org/10.1161/STROKEAHA.116.016027>; PMID: 28428346.
 146. Gardener H, Elkind MSV. Artificial Sweeteners, Real Risks. *Stroke* 2019;50:549–51. <https://doi.org/10.1161/STROKEAHA.119.024456>; PMID: 30760171.
 147. Zheng Y, Li Y, Huang T, Cheng HL, et al. Sugar-sweetened beverage intake, chromosome 9p21 variants, and risk of myocardial infarction in Hispanics. *Am J Clin Nutr* 2016;103:1179–84. <https://doi.org/10.3945/ajcn.115.107177>; PMID: 26961926.
 148. World Health Organization. *Guideline: Sugars Intake for Adults and Children*. Geneva: World Health Organization, 2015.
 149. Micha R, Penalvo JL, Cudhea F, et al. Association between dietary factors and mortality from heart disease, stroke, and type 2 diabetes in the United States. *JAMA* 2017;317:912–24. <https://doi.org/10.1001/jama.2017.0947>; PMID: 28267855.
 150. Yang Y, Zhao LG, Wu QJ, et al. Association between dietary fiber and lower risk of all-cause mortality: a meta-analysis of cohort studies. *Am J Epidemiol* 2015;181:83–91. <https://doi.org/10.1093/aje/kwu257>; PMID: 25552267.
 151. Bozzetto L, Costabile G, Della Pepa G, et al. Dietary Fibre as a Unifying Remedy for the Whole Spectrum of Obesity-Associated Cardiovascular Risk. *Nutrients* 2018;10:pii:E943. <https://doi.org/10.3390/nu10070943>; PMID: 30037123.
 152. Wu Y, Qian Y, Pan Y, et al. Association between dietary fiber intake and risk of coronary heart disease: A meta-analysis. *Clin Nutr* 2015;34:603–11. <https://doi.org/10.1016/j.clnu.2014.05.009>; PMID: 24929874.
 153. Papas AM. Diet and antioxidant status. *Food Chem Toxicol* 1999;37:999–1007. [https://doi.org/10.1016/S0278-6915\(99\)00088-5](https://doi.org/10.1016/S0278-6915(99)00088-5); PMID: 10541457.
 154. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. *Circulation* 2001;104:2673–8. <https://doi.org/10.1161/hc4601.099485>; PMID: 11723017.
 155. Bailey RL, Gahche JJ, Lentino CV, et al. Dietary supplement use in the United States, 2003–2006. *J Nutr* 2011;141:261–6. <https://doi.org/10.3945/jn.110.133025>; PMID: 21178089.
 156. Chun OK, Floegel A, Chung SJ, et al. Estimation of antioxidant intakes from diet and supplements in U.S. adults. *J Nutr* 2010;140:317–24. <https://doi.org/10.3945/jn.109.114413>; PMID: 20032488.
 157. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. *Lancet* 1999;354:447–55. [https://doi.org/10.1016/S0140-6736\(99\)07072-5](https://doi.org/10.1016/S0140-6736(99)07072-5).
 158. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. *N Engl J Med* 1996;334:1145–9. <https://doi.org/10.1056/NEJM199605023341801>; PMID: 8602179.
 159. Lawson KA, Wright ME, Subar A, et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. *J Natl Cancer Inst* 2007;99:754–64. <https://doi.org/10.1093/jnci/dkj177>; PMID: 17505071.
 160. Vivekananthan DP, Penn MS, Sapp SK, et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. *Lancet* 2003;361:2017–23. [https://doi.org/10.1016/S0140-6736\(03\)13637-9](https://doi.org/10.1016/S0140-6736(03)13637-9); PMID: 12814711.
 161. Moyer MW. The myth of antioxidants. *Sci Am* 2013;308:62–7. <https://doi.org/10.1038/scientificamerican0213-62>; PMID: 23367786.
 162. Hasnain BI, Mooradian AD. Recent trials of antioxidant therapy: what should we be telling our patients? *Cleve Clin J Med* 2004;71:327–34. <https://doi.org/10.3949/ccjm.71.4.327>; PMID: 15117174.
 163. Bahrami Soltani R, Ebrahimi F, Farzaei MH, et al. Dietary polyphenols for atherosclerosis: A comprehensive review and future perspectives. *Crit Rev Food Sci Nutr* 2019;59:114–132. <https://doi.org/10.1080/10408398.2017.1360244>; PMID: 28812379.